Study of two immunotherapy drugs for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with newly diagnosed rectal adenocarcinoma that has not spread. The goal is to see if this treatment can shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal adenocarcinoma (a type of rectal cancer) confirmed by biopsy.
- Tumor is at or below 15 cm from the anal opening by colonoscopy and is stage cT3/cT4 N0 or cT(any) N1/2 (locally advanced but not spread to distant organs).
- No signs of cancer spread to other parts of the body (no distant metastases).
- Your tumor shows intact mismatch repair proteins (called pMMR or MSS), meaning it is not the MSI-H type.
- You have not had prior radiation, chemotherapy, or surgery for rectal cancer.
- You are age 18 or older and have a good performance status (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (botensilimab and balstilimab) given before surgery for early-stage rectal cancer that is MSS/pMMR. The goal is to see if this treatment can shrink the tumor and improve outcomes compared to standard care.
This trial tests a new combination of two immunotherapy drugs (called anti-PD-1 and anti-CTLA-4) for people with stage II or III rectal cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes before surgery or as part of the main treatment.
This trial tests two immunotherapy drugs, botensilimab and balstilimab, for people with colorectal cancer who have had surgery and chemotherapy but still have detectable cancer DNA in their blood. The goal is to see if these drugs can help clear the remaining cancer cells.
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
This trial tests a combination of chemotherapy (FOLFOX) and two immunotherapies (botensilimab and balstilimab) before surgery for patients with localized rectal cancer. It aims to see if adding immunotherapy helps shrink the tumor and improve outcomes.
Hear when a new Locally Advanced Rectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.